KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

We worked with KalVista Pharmaceuticals to study Oral KVD900 in Patients with Hereditary Angioedema (HAE) in this phase II clinical trial. Results included the observation that attacks treated with KVD900 significantly reduced use of rescue with 15% of KVD900 treated attacks rescued compared to 30% on placebo at 12 hours.

Back to Clinical Trial Publications Archive